A Phase 2b, Controlled, Observer-Blind, Multi-Center Study Assessing the Effectiveness, Immunogenicity and Safety of the 3rd Dose of Novartis Meningococcal ABCWY Vaccine Administered to Healthy Adolescents in the U.S.

Trial Profile

A Phase 2b, Controlled, Observer-Blind, Multi-Center Study Assessing the Effectiveness, Immunogenicity and Safety of the 3rd Dose of Novartis Meningococcal ABCWY Vaccine Administered to Healthy Adolescents in the U.S.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Mar 2017

At a glance

  • Drugs Meningococcal vaccine groups A B C Y W-135 conjugate (Primary)
  • Indications Meningococcal group A infections; Meningococcal group B infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Meningococcal infections
  • Focus Therapeutic Use
  • Sponsors Novartis Vaccines
  • Most Recent Events

    • 21 Jul 2015 Status changed from active, no longer recruiting to completed, according to to ClinicalTrials.gov record.
    • 31 Mar 2015 Planned End Date changed from 1 May 2015 to 1 Jun 2015, according to to ClinicalTrials.gov record.
    • 18 Feb 2015 Planned End Date changed from 1 Feb 2016 to 1 May 2015, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top